2020    MASCC announces the Study Group Leadership changes for 2020/2022. For the full roster of study group leaders, visit individual study groups on the MASCC website.  Be sure to stay in touch with your Study Groups and get involved in their projects. It's the best way to take full advantage of your MASCC membership and work with like-minded colleagues around the world. Contact Study Group Coordinator Leslie Johnson for more information.

2020    For the benefit MASCC members, Ourania Nicolatou-Galitis, DDS, MSc, DrDent, has shared updates on the publication of two recent articles in Oral Diseases. The first is“Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents,” which includes MASCC member study participants Ourania Nicolatou-Galitis, Erofili Papadopoulou, Emmanouil Vardas, Maria Kouri, Dimitra Galiti, and Carla Ripamonti.

2019    A new MASCC/ISOO/ASCO Clinical Practice Guideline on Medication-Related Osteonecrosis of the Jaw has been published in the Journal of Clinical Oncology (JCO) by the American Society of Clinical Oncology. (Yarom N et al, J Clin Oncol 2019 Jul 22:JCO1901186. Epub ahead of print). 

2015    In September, 2014, The European Society for Medical Oncology (ESMO) published clinical practice guidelines for maintaining bone health in patients with cancer. The guidelines address both multidisciplinary treatments for reducing skeletal effects of metastatic disease and strategies for minimizing treatment-induced skeletal damage. The guidelines article was published in the Annals of Oncology by R. Coleman, J. J. Body, M. Aapro, P. Hadji, and J. Herrstedt on behalf of the ESMO Guidelines Working Group.*

2012    Carolinas HealthCare System (CHS) Receives $8 Million NIH Grant to Conduct First-Ever Study of its Kind. CHS’s Carolinas Medical Center has been awarded an $8 million grant from the National Institute of Dental and Craniofacial Research (NIDCR) to study dental and oral medicine outcomes of patients who have received high-dose radiation to the head and neck region. This is the largest research grant ever awarded to CHS. As the awardee organization, CHS will administer the grant, which will be shared across the several sites involved in the study. Each year 40,000 Americans develop head and neck cancer, and many have to receive high-dose radiation therapy, often in combination with surgery and/or chemotherapy. An unavoidable side effect of radiation therapy is damage to the oral and maxillofacial tissues, some of which persist for the lifetime of the patient.